Pharmaceuticals Global News & Press Release Distribution

Pharmaceuticals

All
APAC

Accro Bioscience Announces $50 Million Series C Financing Led by OrbiMed to Advance Clinical Pipeline for Immune Mediated Diseases

* Financing led by OrbiMed with participation from TCGX, LAV, Cenova Capital and existing investors SCGC and Oriza * Proceeds will advance multi-asset pipeline including AC-101, a leading RIPK2 inhibitor for Ulcerative Colitis NEW YORK and SUZHOU, China, May 18, 2026 /PRNewswire/ -- Accro Bio...

2026-05-19 08:00 4308

Innovent Showcased Clinical and Preclinical Results of Next-Generation Autoimmune and Ophthalmology Pipeline at the 2026 ATS and ARVO Conferences

SAN FRANCISCO and SUZHOU, China, May 18, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...

2026-05-19 08:00 5251

Major breakthrough of Sanyou Biopharmaceuticals AI-STAL

SHANGHAI, May 18, 2026 /PRNewswire/ -- Sanyou Biopharmaceuticals announced today that its independently developed AI-STAL has undergone a significant upgrade, successfully achieving a qualitative leap from "molecular treasure trove" to "intelligent engine", marking the company's entry into a new ...

2026-05-18 22:00 5193

Bambusa Therapeutics Presents Positive Preliminary Phase 1 BBT002 Data at American Thoracic Society 2026 (ATS 2026) International Conference and Announces First Patient Dosed in Phase 1b/2a CRSwNP Trial

- BBT002 is a next-generation, long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-5 - - Preliminary Phase 1 data demonstrated rapid, deep, and sustained effects on key biomarkers for at least 8 weeks following a single dose, including pSTAT6...

2026-05-18 21:15 6054

Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development

* Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra®. * Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axill...

2026-05-18 21:00 4012

Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development

Earendil Labs Announces First Cohort Dosed in Phase I Study of Novel Biparatopic Antibody Targeting Thymic Stromal Lymphopoietin (TSLP)

WILMINGTON, Del., May 18, 2026 /PRNewswire/ -- Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, today announced the successful completion of cohort 1 dosing in a phase I clinical trial for a novel biparatopic antibody targeting Thymic...

2026-05-18 19:00 4555

Harbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate

Hu-mAtrIx™-Enabled Next-Generation ACVR2A/2B- Targeting Antibody Demonstrates Potential to Become a Best-in-Class Therapy for Obesity CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, May 17, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical compan...

2026-05-18 08:03 4038

Atisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the Board

* RB042 Phase 1 trial advances into multiple ascending dose study cohorts, demonstrating safety and tolerabilityto date. * Dr. Coulie brings more than 25 years of international biopharma leadership and deep expertise in pulmonary disease to the Atisama Board of Directors. MELBOURNE, Australia...

2026-05-15 22:25 8994

Racura Oncology Announces Positive Safety Review Committee Recommendation in ongoing CPACS Clinical Trial

Safety Review Committee (SRC) gives Racura Oncology a recommendation to continue the Cardioprotection and Anticancer Synergy (CPACS) study in advanced solid tumor patients SYDNEY, May 15, 2026 /PRNewswire/ -- Racura Oncology, an Australian Phase 3 stage clinical biopharmaceutical company, today ...

2026-05-15 19:06 4646

Phase II Data from a Randomized Double-Blind Trial of Ligufalimab (Anti-CD47) Combination Therapy in Frontline AML Published at EHA 2026

HONG KONG, May 15, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that compelling results from its randomized, double-blind, placebo-controlled Phase II trial (AK117-206) of ligufalimab (AK117) will be presented as an oral presentation at the 2026 European ...

2026-05-15 15:43 4969

SN BioScience Doses First Patient in Phase 1b/2 Clinical Trial of 'SNB-101'

SEONGNAM, South Korea, May 14, 2026 /PRNewswire/ -- SN BioScience Inc., a clinical-stage biotechnology company based in South Korea, announced today that it has initiated the first patient dosing in its global Phase 1b/2 clinical trial evaluating SNB-101 (API: SN-38), a nanoparticle anticancer ag...

2026-05-15 07:03 3745

POMDOCTOR LIMITED Announces Fiscal Year 2025 Financial Results

GUANGZHOU, China, May 14, 2026 /PRNewswire/ -- Pomdoctor Limited ("Pomdoctor" or the "Company") (NASDAQ: POM), a leading online medical services platform for chronic diseases in China, today announced its financial results for the fiscal year ended December 31, 2025. Mr. Zhenyang Shi, Chairman a...

2026-05-15 04:30 6795

OnCusp Therapeutics Appoints Anthony Kim as Chief Financial Officer

PRINCETON, N.J., May 14, 2026 /PRNewswire/ -- OnCusp Therapeutics, Inc., a clinical-stage biopharmaceutical company developing differentiated oncology therapies designed to translate cutting-edge innovation into clinically meaningful outcomes for patients, today announced the appointment of Antho...

2026-05-14 21:00 3143

Yuyu Pharma's Mervyn's Petcare Launches Cat Dental Care Treat on Amazon, Marking First Overseas Pet Health Push

SEOUL, South Korea, May 14, 2026 /PRNewswire/ -- Mervyn's Petcare, the U.S. subsidiary of Korea-based Yuyu Pharmaceutical (KRX: 000220), has launched its first cat dental care nutritional supplement product, "Ari's Purrfect Dental Bites

2026-05-14 21:00 4572

METiS TechBio, the World's First Publicly Listed AI-Powered Drug Delivery Company, Debuts on the Hong Kong Stock Exchange, "The SpaceX of Pharmaceuticals" Ushers in a New Era of Biopharmaceuticals

HONG KONG, May 13, 2026 /PRNewswire/ -- METiS TechBio (7666.HK), a tech-bio company focused on AI-powered nanodelivery innovation, today successfully listed on the Hong Kong Stock Exchange (HKEX), becoming the world's first publicly listed AI-powered drug delivery company and the first AI-powered...

2026-05-14 10:09 4049

METiS TechBio, the World's First Publicly Listed AI-Powered Drug Delivery Company, Debuts on the Hong Kong Stock Exchange,

Piramal Pharma Solutions Unveils State-of-the-Art Payload-Linker Suite at its Riverview, Michigan Facility

* The Riverview facility provides comprehensive services for active pharmaceutical ingredients (APIs) and high potency APIs (HPAPIs), including specialized solutions for payload-linkers. * This cutting-edge suite will significantly enhance the company's ability to support global payload-linke...

2026-05-13 22:45 3518

Piramal Pharma Solutions Unveils State-of-the-Art Payload-Linker Suite at its Riverview, Michigan Facility

New Nature Communications Publication Highlights Efsubaglutide Alfa's Effects on Glycaemia and β-Cell Function

HONG KONG, May 12, 2026 /PRNewswire/ -- A major new clinical study, SUPER 2, has been published in Nature Communications, reporting that Efsubaglutide Alfa, a long-actingGLP-1 receptor agonist, significantly improved glycaemic control in adults with type 2 diabetes inadequately controlled on metf...

2026-05-13 11:47 3350

New Nature Communications Publication Highlights Efsubaglutide Alfa's Effects on Glycaemia and β-Cell Function

WuXi Biologics Included in 2026 Dow Jones Best‑in‑Class World Index and Emerging Markets Index

SHANGHAI, May 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that, in recognition of its continued efforts and exceptional performance in advancing sustainability, the Company has been included i...

2026-05-13 11:33 4099

Innovent to Present Multiple Clinical and Preclinical Results of Mazdutide and Next-Generation Obesity & Metabolic Pipeline at the 2026 ADA Scientific Sessions

SAN FRANCISCO and SUZHOU, China, May 12, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...

2026-05-13 08:00 4474

Porton Advanced and Dark Horse Consulting Group Announce Memorandum of Understanding Providing A Streamlined Path to Conducting IITs in China

CRANBURY, N.J. and SUZHOU, China, May 12, 2026 /PRNewswire/ -- Porton Advanced, a premier contract development and manufacturing organization (CDMO) specializing in Advanced Therapy Medicinal Products (ATMPs), and Dark Horse Consulting Group ("DHCG" or "the Group"), a leader in strategic and oper...

2026-05-12 23:00 4908

1 2 3 456 7 8 ... 160